Market Signal Briefing

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market.

VLX-1005 is a novel, potent, selective small-molecule inhibitor of 12-LOX, a key pathway driving immune platelet-mediated inflammation and a contributor to the pathogenesis of HIT. This potentially life-threatening complication can occur in up to 5% of patients exposed to heparin – the most commonly used parenteral anticoagulant - regardless of dose, schedule, or route of administration. HIT antibodies can cause catastrophic and life-threatening arterial and venous thrombosis. Approximately 300,000 patients in the United States are evaluated each year for suspected HIT, and an estimated 56,000 confirmed diagnoses occur each year. Mortality and thromboembolic event (TE) rates remain high despite currently available therapies.

Two Phase 1 studies of VLX-1005 in healthy participants have demonstrated that VLX-1005 was well tolerated, with no deaths, no serious adverse events, and no trend in adverse event reporting with increasing doses. A recent Phase 2 study (VLX-1005-003) evaluated VLX-1005 in individuals with suspected HIT, and interim results demonstrated encouraging reductions in thromboembolic events. These events have become a preferred, clinically meaningful endpoint for regulators, clinicians, and payers, given the rising rates observed in current HIT populations.

VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation therapeutics targeting 12-LOX are also under development for type 1 diabetes and other immune-mediated and inflammatory diseases.

“We are pleased the advancement of VLX-1005 for the treatment of HIT will continue under the leadership of Cadrenal,” said Matthew Boxer, Co-Founder of Veralox Therapeutics. “The program has found a home in Cadrenal, where it aligns with a shared vision and excitement regarding the promise 12-LOX technology may offer patients.”

“With the acquisition of VLX-1005, Cadrenal continues to advance novel therapeutics to treat or prevent thrombosis in high-risk patients,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “HIT remains a dangerous condition without a therapy that addresses its immune-driven biology. The emerging data from VLX-1005 suggest meaningful potential to improve patient outcomes while maintaining favorable tolerability. We believe this is a compelling strategic addition to our pipeline, with the market size for HIT reaching $1 billion in the US and EU.”

Under the terms of the acquisition agreement, Veralox is eligible to receive upfront and milestone payments contingent on the achievement of specified future clinical and regulatory milestones. Additionally, Veralox will be entitled to royalties on global sales of the acquired assets upon future commercialization. The structure and terms of the agreement enable Cadrenal to allocate capital to advancing the clinical development of VLX-1005.

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding advancing VLX-1005 for the treatment of HIT; continuing to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the emerging data from VLX-1005 suggesting meaningful potential to improve patient outcomes while maintaining a favorable safety profile; VLX-1005 being a compelling strategic addition to Cadrenal’s pipeline; the payment to Veralox of milestone payments contingent upon the achievement of certain future clinical and regulatory milestones as well as royalties on global sales of the acquired assets upon future commercialization; the structure and terms of the agreement enabling Cadrenal to allocate capital to advancing the clinical development of VLX-1005; and developing transformative therapeutics to overcome the limitations of current anticoagulation therapy. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to advance the clinical development of VLX-1005 for the treatment of HIT; the ability to continue to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
[email protected]

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
[email protected]

Logo (PRNewsfoto/TransCode Therapeutics, Inc.)

QL logo

, /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform.

The PRE-I-SPY program will incorporate TTX-MC138 in a Phase 2a dose-expansion clinical trial enrolling up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and are ctDNA positive. The Phase 2a portion of the trial is planned to begin in the first half of 2026 and will be led by Principal Investigator Dr. Paula Pohlmann of MD Anderson Cancer Center.

This clinical trial aims to evaluate the biological and clinical activity of TTX-MC138 in the Minimal Residual Disease (MRD) setting, where the therapeutic intervention may have the greatest opportunity to improve long-term outcomes. The decision to test TTX-MC138 in patients who have demonstrated a pathological complete response following standard-of-care therapy but have evidence of circulating tumor DNA (ctDNA) is based on the high degree of recurrence in those patients and the lack of effective therapies in that setting. TTX-MC138 offers a therapeutic option in that setting because of the drug's mechanism of action specifically targeting metastatic disease combined with an excellent safety profile.

"The safety and durable clinical benefit observed in TransCode's Phase 1a trial with TTX-MC138 provide the basis for TransCode's decision to proceed with Phase 2a clinical testing", noted Daniel Vlock, MD, TransCode's Consulting Clinician. "The observed safety profile, coupled with the durability of TTX-MC138's anti-tumor effects, is particularly encouraging. These findings are consistent with the drug's mechanism of action and provide a basis for a more rigorous efficacy evaluation. This positions us to potentially intervene earlier in the patient's disease, offering a new therapeutic option for patients at risk of developing metastatic disease."

"Detecting and treating micrometastatic disease before it becomes visible is one of the biggest unmet challenges in cancer," said Laura Esserman, M.D., co-founder of Quantum Leap, and Professor of Surgery and Radiology at the University of California, San Francisco. "The PRE-ISPY Trial is uniquely positioned to rapidly evaluate agents like TTX-MC138 that may eradicate minimal residual disease and prevent recurrence in colorectal and eventually other cancer. We are excited to collaborate with TransCode to accelerate this program, with the goal of advancing effective, less toxic precision therapies into Phase 2 and beyond—where the potential to truly cure patients exists."

About TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's Phase 1a first-in-human clinical trial achieved its primary safety endpoint and established a recommended Phase 2 dose, as announced at ESMO 2025.

About TransCode Therapeutics 

TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers.  The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit www.transcodetherapeutics.com.

About the I-SPY TRIALs

The I-SPY ("Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis") Trials were designed to rapidly screen promising experimental treatments and identify those most effective for biologically defined patient subgroups. The trials represent a unique collaboration among the U.S. Food and Drug Administration, industry partners, patient advocates, philanthropic sponsors, and clinicians across leading U.S. cancer research centers. Quantum Leap Healthcare Collaborative is the trial sponsor and oversees all operational, regulatory, and data-integration activities. The PRE-ISPY platform extends I-SPY into early feasibility testing to accelerate biologically targeted therapies into the I-SPY 2.2 high-risk curative setting. For more information, visit www.ispytrials.org.

About Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative is a 501(c)(3) nonprofit organization founded in 2005 by UCSF researchers and Silicon Valley innovators. Its mission is to integrate clinical care with research, advance high-impact platform trials, and improve patient outcomes through adaptive learning systems, enhanced data infrastructure, and widespread trial accessibility. Quantum Leap sponsors and manages the I-SPY Trial programs. For additional information, visit www.quantumleaphealth.org.

Forward-Looking Statements 

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of TransCode's collaborations with Quantum Leap, TransCode's Phase 1a clinical trial, TransCode's planned Phase 2a clinical trial, and the incorporation of TTX-MC138 into the PRE-I-SPY program for a Phase 2a dose-expansion clinical trial, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode's TTX-MC138 and other therapeutic candidates. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in TransCode's Annual Report on Form 10-K for the year ended December 31, 2024, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes no duty to update this information unless required by law. 

SOURCE TransCode Therapeutics, Inc.

Key Takeaways XOM posts record 1.7M boe/d and expands Midland acreage, boosting its upstream outlook.Record 700,000 bpd from Guyana and low breakeven costs help XOM endure weaker oil prices.XOM shares rose 10.7% in a year and trade at 7.76X EV/EBITDA with steady 2025 estimates.
Exxon Mobil Corporation (XOM - Free Report) is among the largest integrated energy companies, but generates the majority of its earnings from upstream operations. The energy giant has a strong presence in the Permian, the most prolific oil and gas resource in the United States, and offshore Guyana. Thus, XOM’s upstream business outlook seems bright.

On the third-quarter earnings call, ExxonMobil stated that it has generated another record production of 1.7 million oil-equivalent barrels per day. Following its strategic push on broadening its presence in advantageous assets, XOM mentioned its acquisition of more than 80,000 premium acres in the Midland, a sub-basin of the broader Permian, from Sinochem Petroleum.

ExxonMobil also highlighted that it has achieved record production of more than 700,000 barrels per day from Guyana. Notably, ongoing operations in advantageous assets like Permian and Guyana seem profitable since breakeven costs are low. Therefore, XOM can manage the business environment even when oil prices fall.

FANG & COP Also Have Footprint in the PermianDiamondback Energy Inc. (FANG - Free Report) and ConocoPhillips (COP - Free Report) also have a strong presence in the Permian. FANG is a Permian pure-play player with sufficient drilling inventory to sustain its production for more than 10 years.

ConocoPhillips’ assets in the Lower 48 comprise resources in the prolific Delaware and Midland basins. The Delaware Basin contributes considerably to COP’s Lower 48 production. Thus, both FANG and COP can sail through low oil prices.

XOM’s Price Performance, Valuation & EstimatesShares of XOM have gained 10.7% over the past year compared with the 9% improvement of the composite stocks belonging to the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, XOM trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 7.76X. This is above the broader industry average of 4.82X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for XOM’s 2025 earnings has seen no revisions over the past seven days.

Image Source: Zacks Investment Research

ExxonMobil currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company’s fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its “inherent strength” and “the underlying momentum in our strategy.” The Company also stated on May 20, 2025, that it was seeing “normal stock levels” among its customers and that it was “seeing performance in the month to date as we would expect.”

As alleged, in truth, the Company’s North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered “in April through May” as customers “made efforts to return to more normal inventory levels[.]” The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

On November 17, 2025, James Hardie announced that Rachel Wilson had decided to step down from her role as CFO.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Freeport securities. The case is pending in the U.S. District Court for the District of Arizona and is captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243.

Why is Freeport Being Sued For Securities Fraud?

Freeport is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia (“PTFI”). PTFI operates the Grasberg Copper and Gold Mine (“Grasberg”), in which the Indonesian government holds a commercial interest. During the relevant period, Freeport touted its safety procedures, including its use of data and technology as well as behavioral science principles to prevent fatal incidents. It indicated it provides the training, tools, and resources needed to identify risks and consistently apply effective controls.

As alleged, in truth, Freeport overstated its commitment to safety, given that it conducted unsafe mining practices at the Grasberg mine which were reasonably likely to result in worker fatalities.

Why did Freeport’s Stock Drop?

On September 9, 2025, Freeport issued a press release on its PTFI operations. It announced that mining operations in Grasberg had been suspended to evacuate seven team members that were trapped due to a landslide at one of its underground mines. This news caused the price of Freeport stock to drop $2.77 per share, or more than 5.9%, from a closing price of $46.66 per share on September 8, 2025, to $43.89 per share on September 9, 2025.

On September 24, 2025, Freeport issued an update on the incident noting that two of the seven individuals had been fatally injured and that the remaining five team members remained missing. In the same release, Freeport noted that due to the suspension in operations, sales were expected to be 4% lower for copper and approximately 6% lower for gold than July 2025 estimates. This news caused the price of Freeport stock to drop $7.69 per share, or almost 17%, from a closing price of $45.36 per share on September 23, 2025, to $37.67 per share on September 24, 2025.

Then, on September 25, 2025, Bloomberg reported that the incident and halt in production was straining the relationship between Freeport and Indonesia, that “the Jakarta government [had already been] looking to take greater control,” and that government officials may increase its demand for an increased share. This news caused the price of Freeport stock to drop $2.33 per share, or more than 6%, from a closing price of $37.67 per share on September 24, 2025, to $35.34 per share on September 25, 2025.

Finally, on September 28, 2025, an Indonesian news organization reported that the incident was preventable, not just a natural disaster. The article quotes an Indonesian professor stating that “the landslide, often termed a mud rush, is a known flow of mud and rocks from the mine cavity, a risk long associated with certain mining methods.” The professor stated, “[i]n other words, this danger is not new and should have been anticipated from the beginning[.]”

Click here for more information: https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit.

What Can You Do?

If you invested in Freeport you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/freeport-mcmoran-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

Investors have until January 26, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv- 11319.

Why is Alexandria Real Estate Being Sued For Securities Fraud?

Alexandria Real Estate is a real estate investment trust. Its tenants are concentrated in life science industries, such as pharmaceutical and biotechnology companies.

During the relevant period, Alexandria Real Estate touted its leasing volume and development pipeline, specifically regarding a property in Long Island City, New York, stating that leasing volume was “solid” and its pipeline was “well positioned to capture future demand when expansion needs arise.”

As alleged, in truth, Alexandria Real Estate was experiencing lower occupancy rates and slower leasing activity such that it was required to take a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property.

Why did Alexandria Real Estate’s Stock Drop?

On October 27, 2025, Alexandria Real Estate announced results below expectations for 3Q 2025 and cut guidance for the remainder of the fiscal year. The company attributed the results to lower occupancy rates and slower leasing activity. It also announced a real estate impairment charge of $323.9 million with $206 million attributed to its Long Island City property, stating that the property was not a life science destination that could scale. Alexandria Real Estate also announced additional impairment charges that may be recognized in 4Q 25 ranging from $0 to $685 million. This news caused the price of Alexandria Real Estate stock to drop $14.93 per share, or more than 19%, from a closing price of $77.87 per share on October 27, 2025, to $62.94 per share on October 28, 2025.

Click here for more information: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

What Can You Do?

If you invested in Alexandria Real Estate you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection

• Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection

• Designed for early detection of conditions that are related to the most common cancers and chronic diseases

• Rapid, easy-to-use, and cost-effective screening for mass and individual use

IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today that the Egyptian Drug Authority (EDA) has granted authorization for Biomerica’s complete portfolio of rapid tests, enabling broad access to simple, rapid, and affordable early detection tools for conditions associated with cancers and chronic diseases across Egypt.

This authorization allows Biomerica’s screening products to be marketed and distributed throughout Egypt, supporting early identification of conditions associated with colorectal, breast, and prostate cancers, as well as chronic diseases including kidney disease and Helicobacter pylori infection.

Comprehensive Screening Portfolio Now Authorized in Egypt

The EDA authorization covers the following Biomerica at-home tests:

EZ Detect™ Colon Disease Test – The most convenient fecal occult blood test (FOBT) that detects hidden blood in stool, an early warning sign of colorectal diseases such as polyps and colorectal cancer. Results are available within two minutes, with no stool handling required.Aware® Breast Self Exam – An aid designed to enhance breast self examination by improving tactile sensitivity and allowing users to detect changes in breast tissue more effectively, supporting early detection of breast abnormalities, including potential indicators of cancer.Fortel Prostate (PSA) Screening Test – A rapid lateral flow test using a finger-prick whole blood sample to detect elevated Prostate Specific Antigen (PSA) levels, which may indicate prostate disease including prostate cancer.Fortel Kidney Disease (Microalbumin) Screening Test – Detects elevated levels of human albumin in urine, an early marker of possible kidney damage, supporting early identification of chronic kidney disease risk.Fortel Ulcer (H. pylori) Screening Test – A rapid whole blood test detecting antibodies to Helicobacter pylori infection, which is associated with gastritis, ulcers, and in some cases stomach cancer. All tests are designed for point-of-care use enabling deployment across diverse clinical and community settings, including regions with limited infrastructure. They provide quick results within minutes, and eliminate the need for laboratory sample processing, reinforcing Biomerica’s commitment to accessible preventive healthcare.

A Significant Unmet Need in Egypt for Screening

Colorectal Cancer (CRC) is a moderately common cancer in Egypt (7th most common) with roughly 5 – 10 cases per 100,000 persons per year, with rising diagnoses at younger ages and a high proportion of cases detected at late stages.

According to the International Agency for Research on Cancer (IARC)/Global Cancer Observatory (GLOBOCAN) the age-standardized incidence rate (ASR, world standard) for breast cancer in females is about 55.4 per 100,000 persons per year. Breast cancer is the most common cancer among women in Egypt by incidence. The mortality outcomes are comparatively worse, which are influenced by later stage at diagnosis as screening and early detection are less prevalent than in high-income countries.

Prostate Cancer is the fourth most common cancer in Egypt with increasing incidence.

Research shows that approximately 13% of adults in Egypt are living with chronic kidney disease according to a population analysis published in the Journal of Public Health in Africa. Additionally, CKD ranked among the top five causes of death in Egypt from 2009 to 2019, highlighting the severity and increasing burden of the disease.

H. pylori infection in Egypt is highly prevalent; studies report varying prevalences between 50 to 70%, likely affecting a majority of children and many adults.

Strengthening Egypt’s Preventive Healthcare Infrastructure

These screening tools target populations most at risk, including individuals with diabetes, hypertension, family histories of cancer, and other chronic health conditions. By empowering individuals with private, reliable, and rapid home testing, these products support national public health efforts to shift disease detection earlier, improve outcomes, and reduce long-term healthcare costs.

“Authorization of our full screening portfolio by the Egyptian Drug Authority represents a milestone in expanding access to early detection in a region with growing chronic disease and cancer burdens,” said Zack Irani, CEO of Biomerica. “This authorization provides scalable tools for both individual testing and screening initiatives.”

Designed for Population-Level Screening

Biomerica’s screening tests are positioned not only for consumer use but also for public health campaigns, clinics, pharmacies, and hospital-based screening programs, offering:

No lab processing or mailing requirementsLow-cost, scalable solutions for mass screeningQuick turnaround for immediate decision-makingPrivacy and convenience for patients These features allow healthcare providers and government agencies to deploy large-scale screening programs efficiently, particularly in underserved and rural areas.

Expanding Biomerica’s Presence in the Middle East & North Africa

This authorization strengthens Biomerica’s strategic expansion across the Middle East and North Africa (MENA) region and reinforces its role as a provider of affordable, patient-centered diagnostic solutions aligned with global preventive care trends.

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, operations, margins, cost of goods, and earnings; the efficacy, performance, and potential market adoption of the Company’s products and tests, including but not limited to the EZ Detect™ Colon Disease Test, Aware® Breast Self Exam, Prostate (PSA) screening Test, Fortel® Kidney Disease (Microalbumin) Test, H. pylori screening Test, and the Company’s broader screening test portfolio; the Company’s ability to obtain and maintain regulatory authorizations, clearances, or approvals necessary to market or sell any of its current or future products; the Company’s ability to expand into additional domestic or international markets; the uniqueness, clinical utility, accuracy, potential benefits, and commercial acceptance of the Company’s products; pricing of the Company’s test kits; domestic and/or international demand for the Company’s products; future availability of the Company’s products in pharmacies, clinics, hospitals, or through public health programs; and the potential use of the Company’s products by physicians and healthcare organizations. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results, including, without limitation: results of studies testing the efficacy or performance of the Company’s products; regulatory requirements and the ability to obtain or maintain necessary approvals; supply-chain challenges and dependence on third-party manufacturers and shipping carriers; governmental import/export regulations; competitive products and companies with significantly greater financial and operational resources; governmental healthcare policies; demand for the Company’s various tests; pricing pressures; reimbursement challenges; the Company’s ability to raise additional capital; general economic conditions; and the Company’s ability to protect its intellectual property. Accordingly, actual results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The Company is under no obligation to update any forward-looking statements after the date of this release.

Corporate Contact:
Zack Irani | CEO
p. 949.645.2111
www.biomerica.com

Source: Biomerica

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

Investors have until January 2, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities. The case is pending in the U.S. District Court for the District of Maryland and is captioned Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602.

Why is CarMax Being Sued For Securities Fraud?

CarMax sells used cars. During the relevant period, the Company touted the strong and sustainable demand for its cars, driven by factors such as a seamless customer experience.

As alleged, in truth, it appears that the announcement of U.S. tariffs imposed on cars provided a short-term boost to demand, as customers purchased cars prior to the tariffs taking effect.

BFA Law is also investigating the unexpected departure of CEO Bill Nash on November 6, 2025, and whether CarMax properly assessed or reserved for its portfolio of car loans.

Why did CarMax’s Stock Drop?

On September 25, 2025, the Company reported disappointing financial results for the second quarter of its fiscal year 2026. Specifically, CarMax announced sales declines across the board, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units. The Company also posted a disappointing second quarter net income of about $95.4 million, down from $132.8 million over the prior year. A main reason for the declines, according to CarMax, was a “pull forward” in demand into the first fiscal quarter due to the announcement of tariffs.

On this news, the price of CarMax stock dropped $11.45 per share, or roughly 20%, from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025.

Then, on November 6, 2025, CarMax announced the unexpected departure of CEO Bill Nash and a weak preliminary Q3 2025 outlook. On this news, the price of CarMax stock dropped over 24%.

Click here for more information: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

What Can You Do?

If you invested in CarMax you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

We were watching yesterday whether Chewy could sustain its profitability momentum after a string of strong quarters. The answer came pre-market on December 10: the company beat earnings estimates by 39%, posting $0.32 per share against the $0.23 consensus. The stock surged to $37.34 at the open but gave back most gains through the session, closing at $35.22. This morning, shares are up 1.5% in pre-market trading to $35.37, suggesting investors are still digesting the implications.

The Beat That Validated a Thesis
Chewy’s Q3 results delivered on multiple fronts. Revenue of $3.12 billion beat estimates by $24 million and grew 8.3% year over year. But the real story was profitability: net income hit $59.2 million, up from just $3.9 million in the same quarter last year. That represents a 1,415% increase in bottom-line performance.

The company’s gross margin expanded 50 basis points to 29.8%, and adjusted EBITDA climbed 30.9% to $180.9 million. Free cash flow generation remained strong at $330.4 million for the nine-month period. These aren’t one-time adjustments. This is the fourth consecutive quarter of sustained profitability, with net income ranging between $59 million and $62 million each quarter this fiscal year.

What matters most for valuation: the forward P/E ratio of 25.8x looks dramatically cheaper than the trailing 72.2x multiple, reflecting expectations that earnings will continue accelerating. Yesterday’s beat confirms the market wasn’t overoptimistic.

Management Confidence Meets Measured Reaction
CEO Sumit Singh emphasized that “Chewy continues to outperform the pet category and expand market share, with profits once again growing faster than sales.” He highlighted the company’s “structural resilience” and “execution quality,” pointing to sustainable advantages in a competitive market.

Yet investors took profits after the initial pop. The stock opened at $37.20, peaked at $37.34, then faded throughout the day. Heavy volume at the close (2.05 million shares in the final five minutes) suggests institutional repositioning rather than panic selling. The after-hours stabilization around $35.20 and modest pre-market continuation indicate professionals are accumulating near current levels.

What to Watch From Here
The technical setup remains constructive. The RSI sits at 56.7, leaving room for upside before overbought territory. Analysts maintain a bullish stance, with 71% rating the stock a buy and a $45.10 average price target implying 27% upside from current levels.

We’ll be watching whether the company can maintain this profitability trajectory into Q4, particularly as it approaches the critical holiday shopping season. The market’s measured response suggests investors want to see sustained execution before pushing shares toward the $48.62 52-week high. For now, Chewy has proven it can grow revenue while expanding margins, a rare combination in e-commerce that justifies continued attention.

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.

Copyright 2025 Zacks Investment Research 101 N Wacker Drive, Floor 15, Chicago, IL 60606

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.

Visit Performance Disclosure for information about the performance numbers displayed above.

Visit www.zacksdata.com to get our data and content for your mobile app or website.

Real time prices by BATS. Delayed quotes by Sungard.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.

This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.

Key Takeaways Easing mortgage rates and Fed cuts are improving the setup for a 2026 housing market recovery.LEN, CCS, and GRBK stand out for cost control, land strategy, and operational execution entering 2026. All three builders show signs of margin strength and are positioned to capture demand as sentiment improves.
The U.S. housing market closes 2025 at an inflection point. Supply remains structurally constrained, mortgage rates have begun to ease, and the Federal Reserve has entered a more accommodative stance after holding rates at restrictive levels for nearly two years.

With the central bank delivering its third quarter-point cut of the year on Dec. 10—bringing the benchmark range to 3.5%-3.75%—optimism is building that 2026 could mark the beginning of a gradual housing rebound.

Fed officials now expect only one more cut next year, yet the improved outlook for GDP growth, inflation moderation and a slightly lower projected unemployment rate suggests that affordability conditions may slowly improve.

Against this backdrop, homebuilders with strong execution, disciplined land strategies and operational flexibility are positioned to benefit if mortgage rates continue easing into 2026. Lennar (LEN - Free Report) , Century Communities (CCS - Free Report) and Green Brick Partners (GRBK - Free Report) stand out as well-placed to capture incremental demand as sentiment improves.

Macro Conditions Are Turning More SupportiveThe macro backdrop entering 2026 remains mixed but directionally constructive. Inflation is still elevated—roughly a full percentage point above the Fed’s 2% target—but continues to trend lower. The most recent core PCE reading — released by the Commerce Department — showed a 2.8% increase in September, up from 2.7% in August.

The labor market has softened meaningfully, with several months of volatile job creation, though the September rebound to 119,000 payroll additions suggests the market is not collapsing. Fed Chair Jerome Powell acknowledged the dual challenge — inflation remains too high while labor-market risks linger.

Yet policymakers boosted their 2026 GDP growth outlook to 2.3% from 1.8% and expect inflation to ease to 2.5% from 3% in 2025, setting the stage for improving household confidence.

The shift in mortgage rates is equally important. The 30-year fixed rate has slipped to 6.19% as of Dec. 4, its second weekly decline and down half a percent from a year ago. While still far above the pandemic-era lows, the downward drift marks the first meaningful easing in affordability pressure in over a year. With housing supply shortages still pervasive—particularly in Sun Belt and Mountain West markets—any improvement in financing conditions can translate quickly into stronger new-home demand. Builders with cost discipline, solid margins and land in high-growth regions appear best placed to capture this next phase of the cycle.

Lennar: Positioned to Leverage a Cost-Efficient PlatformLennar enters 2026 with one of the strongest operational setups in the industry. Affordability pressures required heavier incentives in 2025, weighing on fiscal third-quarter margins at 17.5%, but the company preserved volume and efficiency through disciplined pricing and its steady “even-flow” production approach. Late-quarter mortgage rate declines also improved traffic and buyer interest, offering early signs of stabilizing demand heading into 2026.

Cost discipline remains a major advantage. Direct construction costs have fallen in 10 of the past 11 quarters, cycle times have improved to a record 126 days, and inventory is tightly managed with fewer than two completed unsold homes per community. Lennar’s asset-light land strategy, supported by more than 523,000 owned or controlled homesites and over $5 billion in liquidity, allows this Zacks Rank #2 (Buy) builder to scale quickly if mortgage rates approach 6% next year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Although LEN stock has plunged 22.8% in the past year, analysts remain optimistic. The Zacks Consensus Estimate for fiscal 2026 EPS has inched up to $9.07 from $9.01 over the past month, depicting 9.9% growth on 2.2% expected revenue expansion.

Century Communities: Improved Operations Fuel GrowthCentury Communities navigated a soft 2025 demand backdrop by tightening execution and reducing costs. In the third quarter of 2025, it delivered 2,486 homes and posted a 20.1% adjusted homebuilding gross margin, supported by a 3% year-to-date drop in direct construction costs and faster cycle times averaging 115 days, with a third of divisions already at 100 days or less. Affordability remained central as economic uncertainty kept buyers cautious, and adjustable-rate mortgages gained traction, rising to nearly 20% of the third-quarter originations from under 5% early in the year. Century Communities also expanded its community base, up 5% year over year, and expects further growth heading into 2026. With more than 62,000 lots and a stronger balance sheet, the company is positioned for a potential demand rebound.

Notably, CCS stock has lost 25.9% in the past year. Nonetheless, with a Zacks Rank #2, Century Communities’ Zacks Consensus Estimate for 2026 EPS has remained unchanged at $7.57 over the past 30 days, indicating 34.2% growth on 7.2% expected revenue improvement.

Green Brick: Margin Strength and Land AdvantageGreen Brick Partners remains one of the sector’s most profitable builders, sustaining gross margins of more than 30% even as affordability pressures prompted greater incentives in 2025. Third-quarter 2025 margins reached 31.1%, aided by a favorable warranty adjustment tied to better build quality. Sales trends stayed firm, with net orders up 2.4% year over year to a record third-quarter level and cancelations improving to 6.7%. Its focus on infill and infill-adjacent communities in fast-growing Texas markets continues to support pricing power. The company controls more than 41,000 well-located lots, giving it a long margin runway. Construction costs declined, cycle times improved and low leverage at 15.8% positions Green Brick to pursue growth as it expands into Houston in 2026.

GRBK stock has gained 1.2% in the past year. With a Zacks Rank #2, GRBK’s Zacks Consensus Estimate for 2026 EPS has increased to $6.89 from $6.77 over the past 60 days, indicating a 0.3% decline on 1.7% expected revenue improvement.

The 2026 Setup: Supply Imbalance Meets Gradual Rate ReliefThe overarching theme heading into 2026 is simple — the U.S. remains dramatically undersupplied. Years of underbuilding combined with aging housing stock and demographic tailwinds have kept structural demand high. The easing of mortgage rates, even modestly, can spark meaningful incremental sales activity because the affordability equation is so finely balanced.

For Lennar, Century Communities and Green Brick Partners, the combination of lean cost structures, disciplined land strategies, expanding community counts and strong balance sheets places each in a favorable position to benefit from any improvement in buyer sentiment. As mortgage rates trend lower and economic growth stabilizes, these builders offer a compelling way for investors to position for a housing market recovery that appears increasingly plausible in 2026.

TLDR:

Bitcoin’s fourth rejection at $94K returns price to the 89,800 zone, a critical pivot for trend continuation or deeper pullback.
Losing 89,800 may drive BTC toward the 87,600–86,000 support box, where traders watch for controlled reversal signals.
Resistance sits at 91,500 and 91,900–92,000, with a break above this range needed to reattempt the 94,000 ceiling.
Over 403,000 BTC leaving exchanges since 2024 has reduced liquidity, shaping reactions around key technical levels.

Bitcoin Price is reacting to another rejection at the 94,000 zone, marking the fourth time the market has turned away from this level. 

The asset is trading near 90,125 as of writing, sitting just under the 89,800 start-impulse area that serves as a key reference for traders watching the post-FOMC landscape. 

This zone has become a major battleground, with market participants assessing whether the asset will move into a deeper retracement or attempt a fresh recovery attempt toward recent highs.

At the same time, structural shifts in supply remain visible. CoinMarketCap shared Santiment data showing that more than 403,000 BTC has left exchanges since December 2024. ETFs and public companies now hold more Bitcoin than all exchanges combined, creating a tightened liquidity environment that continues to influence how price interacts with major support and resistance levels.

Critical Zones After Bitcoin’s 4th Rejection
Analyst Lennaert Snyder outlined a structured view after the latest rejection at 94,000, stating that Bitcoin has returned to the 89,800 start-impulse zone. 

He noted that losing this support could open a pathway toward the 87,600 support box, which sits near previous lows and an established demand area.

This area remains one of the main downside zones traders are monitoring as the post-FOMC reaction unfolds.

$BTC post-FOMC gameplan.

Bitcoin rejected ~$94,000 resistance for the 4th time, and like I said yesterday, it brought us back to the start impulse.

If we lose the ~$89,800 start impulse here, I'll try to short the continuation to the ~$87,600 support box (take out the low).… pic.twitter.com/sEwau9UF82

— Lennaert Snyder (@LennaertSnyder) December 11, 2025

The 87,600–86,000 range is gaining attention as a region where traders may watch for stabilization. 

Snyder explained that long setups may be considered only after clear reversal signals appear inside this box. With the market still trading below near-term resistance, participants remain cautious around premature entries.

He also stated that Bitcoin could consolidate between 89,800 and 91,500 if neither direction gains momentum. 

The 91,500 level functions as a break-of-structure point that has capped several short-term recovery attempts. Many traders are considering tactical shorts near this resistance if it continues to hold.

Resistance Levels That Could Trigger Momentum
Snyder added that reclaiming 91,900–92,000 remains essential for any renewed bullish scenario. 

This top-resistance box has repeatedly acted as a ceiling, and a clean break above it could set the stage for another attempt toward the 94,000 region. Without this reclaim, upward continuation remains limited.

He also described the area between 91,500 and 91,900 as a zone where rejections may still favor short setups. 

Traders watching this region are preparing for either failures or successful retests, depending on how the market reacts after FOMC volatility settles.

Meanwhile, long setups remain concentrated at the lower support box between 87,600 and 86,000 or above the 91,900 breakout area. 

Combined with the ongoing shift of Bitcoin from exchanges to institutional holdings, the market continues to operate within tight liquidity pockets that shape each key inflection point.

Solana price continues to trade in a tightening range as bulls defend support but fail to reclaim major resistance levels. Despite several attempts to stabilize, overhead supply zones and fading momentum have kept SOL capped throughout December. Liquidity fatigue across the broader market, reduced risk appetite, and heavy sell pressure near previous breakdown areas have combined to restrict upside. In this environment, Solana’s next directional move will depend on whether buyers can finally overcome the stubborn resistance bands that have repeatedly halted progress.

Solana’s Current Setup: A Market Stuck in NeutralSolana price remains trapped in a narrow consolidation range after failing to reclaim its major breakdown levels from November. Despite broader market efforts to recover, the SOL price continues to show muted momentum as sellers defend every rally near the mid-channel zone. The current structure reflects indecision: bulls are protecting support but lack the strength to push prices beyond resistance. With volatility compressing and volume tapering, the next breakout from this range will likely dictate Solana’s path heading into early 2026.

The chart reveals Solana trading inside a descending corrective channel, repeatedly rejecting the upper boundary near $142–$145 while stabilizing around $126. Volume continues to thin out, suggesting weaker conviction from both sides of the market. SOL’s inability to reclaim the former support at $150 — now acting as a key resistance shelf—underscores a broader loss of trend strength. A decisive breakout above $145 could open the door toward $160 and $184, while losing $126 exposes deeper support zones at $118 and $105.

Why SOL Is Struggling Despite Attempts to StabilizeSolana’s sideways drift is not just a chart problem—broader structural forces continue to pressure price.

Three Combined Factors Pressuring Solana

Market Liquidity Has Thinned: Stablecoin inflows have slowed across major exchanges, reducing the capital available to fuel breakouts. Low liquidity magnifies resistance reaction zones for altcoins like SOL.ETF and Macro Tailwinds Aren’t Benefiting Altcoins: Bitcoin ETF flows and Fed rate cuts have supported large caps, but money has not rotated into higher-beta assets like Solana. This divergence limits upside momentum.Overhead Supply From $150 to $160: The November breakdown left a heavy cluster of trapped longs above $150. Each rally into this zone triggers profit-taking, keeping SOL pinned inside its channel.Two Possible Scenarios Traders Are WatchingBullish Scenario: Break Above $145 → $160 → $184

A close above $142–$145 with rising volume would invalidate the descending channel and signal early trend recovery. Momentum traders would likely target $160, followed by a larger move toward the $184 resistance block.

Bearish Scenario: Lose $126 → $118 → $105

Failure to defend the mid-range support opens the door to a deeper correction. A drop below $126 puts the range low at risk, and $118 becomes the next logical liquidity target.

Technical Conclusion: Can Solana Reclaim $150–$160 in 2025?Solana’s ability to revisit and reclaim the $150–$160 zone depends on breaking out of its current compression structure. For now, resistance remains firm, and volume remains light—conditions that typically favor sellers. However, if the SOL price maintains support above $126 and broader liquidity conditions improve in early 2025, a retest of the $150 region is still achievable. Without a volume expansion and renewed risk appetite, attempts to reclaim $160 are likely to face strong rejection pressure.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Crypto Markets Today: Traders Seek Catalysts After Bitcoin’s Post-Fed PullbackThe crypto market slipped to the lower end of its range after the Federal Reserve’s 25bps rate cut failed to spark fresh momentum. Dec 11, 2025, 11:30 a.m.

Crypto market remains deflated after Fed rate cut (Getty Images/Modified by CoinDesk)

What to know: BTC is trading near $90,350 after defending the $88,200 support zone, but momentum remains capped below the key $94,500 resistance level.Implied volatility fell to its lowest since November, ETH/BTC IV spreads widened, and risk reversals stayed negative across tenors while open interest declined—most sharply in ADA.Low-liquidity conditions dragged tokens like ETHFI, FET, ADA and PUMP down more than 8%, while privacy-focused XMR stood out with gains as the broader altcoin season index slumped to 19/100.The crypto market tumbled back to the lower side of its range after the Federal Reserve's decision to slash interest rates by 25 baiss points.

The announcement, while bullish for macro assets in the long term, was arguably priced in by traders ahead of the event, with long exposure rapidly unwinding in the subsequent hours.

STORY CONTINUES BELOW

Now, bitcoin remains above the $88,200 level of support, trading at $90,350 as it looks for a catalyst to lift it above this week's stern level of resistance at $94,500.

The altcoin market continues to show weakness as several tokens lost further ground on their respective bitcoin trading pairs.

Derivatives positioningBTC's volatility expectations continue to drop with the Fed decision out of the way. As of writing, the annualized 30-day implied volatility, represented by the BVIV index, was 46.95%, the lowest since Nov. 13. The spread between ether and bitcoin 30-day IVs has risen lately, pointing to renewed market focus on Ethereum's native token. The VIX too has normalized following the November spike. On Deribit, BTC and ETH risk reversals remain negative across tenors, indicating a persistent bias for put options. Block flows featured BTC risk reversals and call calendar spreads and risk reversals and straddles in ETH. In futures market, open interest (OI) in ADA has dropped 10% in 24 hours, leading the decline in OI in most major tokens, including BTC and ETH. The capital flight points to a offloading of risk into the year-end. Funding rates for several top tokens, excluding BTC and ETH, have flipped decisively negative, a sign of traders chasing bearish short positions. Token talkThe altcoin market continued its negative trend on Thursday, retreating back into dangerous territory as the likes of ETHFI, FET, ADA and PUMP all lost more than 8% in the past 24 hours.The sell-off occurred at the same time as bitcoin and ether's respective drawdowns, although the percentage loss was higher as the altcoin market continues to lack liquidity following October's liquidation cascade.Two percent market depth on ETHFI for example is at around $500,000 on either side of the orderbook, meaning that a market order above that figure would move price by more than 2%, which considering the token has a market cap of $480 million is a relatively small trade.A handful of tokens bucked the bearish market trend on Thursday, this included monero XMR$405.60 which rose by more than 2% as it continues to demonstrate a rich vein of form that can be attributed to wider privacy coin strength.CoinMarketCap's "altcoin season" index remains at a lowly 19/100, a far cry from September's high of 77/100 as investors continue to show preference for bitcoin and ether as opposed to more speculative altcoin bets.More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

UK Bitcoin Company Satsuma Sells 579 of Its 1,199 Bitcoin for $53.2 Million

45 minutes ago

The company sells BTC to secure cash for upcoming loan note obligations ahead of its planned uplisting.

What to know:

Satsuma Technology, a U.K.-based bitcoin-focused technology company sold 579 BTC out of its holdings of 1,199 BTC, The sale generated approximately 40 million pounds ($53.2 million) in net proceeds.Following the sale, the company holds 620 BTC and around 90 million pounds in cash. Read full story

Top Stories

2 mins mins

In Brief

Bhutan introduces TER, a gold-backed digital token on Solana blockchain.

TER offers global investors digital gold with on-chain transparency.

Gelephu Mindfulness City drives Bhutan’s blockchain and economic strategy.

Bhutan has launched TER, a gold-backed digital token running on the Solana blockchain. The token is issued through Gelephu Mindfulness City and custodied by DK Bank, Bhutan’s first licensed digital bank. 

This initiative allows international investors to trade a blockchain-based version of physical gold. TER represents a bridge between traditional gold ownership and modern digital finance, providing an innovative investment tool (Bhutan, 2025).

The token’s launch builds on Bhutan’s national blockchain strategy. It positions the country as a leader in integrating physical assets with digital currency ecosystems. 

Gelephu Mindfulness City is launching TER, the world’s first sovereign-backed, physical gold-backed digital token, on Dec 17, 2025. Built on Solana, issued via DK Bank, and powered by Matrixdock tech, TER brings Bhutan’s “Treasure” on-chain with full transparency.… pic.twitter.com/HmJVGh4qPB

— gmcbhutan (@gmcbhutan) December 11, 2025

TER provides users with the mobility, transparency, and efficiency of blockchain, while maintaining the security of gold as an asset (Bhutan, 2025). 

The initiative complements Bhutan’s ongoing digital transformation efforts, which include Bitcoin reserves and blockchain-based identity systems.

Gelephu Mindfulness City Drives Bhutan’s Blockchain Strategy
Gelephu Mindfulness City serves as a key component of Bhutan’s broader economic and technological strategy. It is designed to attract international capital and foster the use of digital assets for the country’s financial reserves. 

The launch of TER underscores Bhutan’s ambition to integrate blockchain into its economic infrastructure, following the example of other small nations like Kyrgyzstan (Bhutan, 2025).

As a part of the country’s push into blockchain technology, Bhutan is focusing on sustainable and transparent financial systems. 

TER offers a secure, accessible way for global investors to gain exposure to gold-backed assets without the complexity of traditional markets (Bhutan, 2025). By combining gold’s stable value with the flexibility of digital currency, Bhutan sets a new standard for national blockchain adoption.

DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.

Rate this post

The New York Stock Exchange displayed a bronze sculpture of Bitcoin's pseudonymous creator, Satoshi Nakamoto, on Thursday. Twenty One Capital, trading under ticker XXI, commissioned the piece as part of a broader artistic campaign spanning multiple countries.

The installation marks the sixth monument in a series of 21 planned sculptures worldwide. Artist Valentina Picozzi created the work, which NYSE representatives characterized as a bridge between traditional finance and digital currencies.

Jack Mallers serves as CEO of Twenty One Capital and founded Strike, a Lightning Network payment platform. He described the statue's placement as evidence of Bitcoin's transformation from digital code to mainstream cultural symbol.

The company's market entrance proved volatile. Shares dropped 19% during Tuesday's debut trading session, according to Bloomberg data. This decline occurred despite the firm's substantial cryptocurrency reserves.

Vandalism Strikes Swiss InstallationThe global statue campaign faced setbacks earlier this year. Vandals targeted a Satoshi monument in Lugano, Switzerland, following Swiss National Day festivities in August. The perpetrators removed the bronze sculpture from Lake Lugano's waterfront.

Investigators determined the thieves used specialized industrial equipment. Evidence suggested tungsten carbide cutting disks and petrol-powered angle grinders severed the welded statue from its concrete base. Only the bronze feet remained attached.

Satoshigallery, the art collective organizing the monument series, offered a bounty for information. The group posted a 0.1 Bitcoin reward, valued near $12,000 at the time. The collective condemned the theft while pledging to continue installations.

The Lugano incident represented the first major destruction of an official Satoshi statue. Budapest launched the campaign with the inaugural monument in September 2021. Other locations include El Salvador's Bitcoin Beach and Tokyo.

Each sculpture carries symbolic meaning. Budapest's piece features a faceless hooded figure with mirrored surfaces reflecting viewers. This design embodies the "we are all Satoshi" philosophy within cryptocurrency communities.

Picozzi's "Disappearing Satoshi" concept takes a different approach. The NYSE statue depicts a seated figure working at a laptop. The sculpture appears to vanish when observers change their viewing angle. The artist expressed surprise at securing the prestigious NYSE location.

Corporate Bitcoin Holdings Face Market PressureTwenty One Capital controls roughly 43,500 bitcoins. Current valuations place this holding above $3.9 billion. The company ranks third globally among corporate Bitcoin holders.

The firm completed a merger with Cantor Equity Partners, a blank-check company backed by Cantor Fitzgerald. Brandon Lutnick chairs the board. His father, Howard Lutnick, currently serves as Commerce Secretary.

The merger structure included $486.5 million in senior convertible notes. Private investment transactions contributed approximately $365 million in common equity. These financial arrangements aimed to strengthen the company's balance sheet.

Market conditions challenged the debut. Shares opened at $10.74 on Tuesday, falling below the SPAC's previous $14.27 close. Digital asset treasury firms currently face scrutiny as Federal Reserve policy creates uncertainty.

The timing intersects with broader cryptocurrency market volatility. Bitcoin prices fluctuate as monetary policy decisions influence investor sentiment. At the time of writing, Bitcoin is trading at around $$90,375, representing a 2.2% decline in the last 24 hours.

BTC price chart, Source: CoinMarketCap

Key NotesJupiter DEX acquired RainFi to accelerate Solana’s on-chain credit markets.The platform appointed former KKR exec Xiao-Xiao J.Zhu as its new president.JUP prices dropped more than 8% in the past 24 hours.
Jupiter Exchange

JUP
$0.21

24h volatility:
6.6%

Market cap:
$673.41 M

Vol. 24h:
$37.61 M

wants a larger piece in Solana’s

SOL
$131.1

24h volatility:
4.3%

Market cap:
$73.56 B

Vol. 24h:
$7.17 B

credit ecosystem and has acquired RainFi, a fixed‑term lending platform behind the Droplets community.

RainFi confirmed that a Droplets snapshot took place on December 10, 2025. All holders at that moment will receive JUP rewards in early 2026 as the project enters the Jupiter ecosystem.

JUST IN: @JupiterExchange has acquired @RainFi_ to accelerate Solana’s onchain credit markets, with Droplets users set to receive $JUP rewards in early 2026. pic.twitter.com/eVTl91ZWnH

— SolanaFloor (@SolanaFloor) December 11, 2025

Jupiter plans a gradual integration of RainFi, which aims to scale credit markets through fixed‑term loans, and its core features over the next few months. Meanwhile the app will continue under its own banner during the transition.

stJUP deposits now remain closed, though users can withdraw from Liquid while rewards continue until the next ASR cycle concludes. On the other hand, stCOLLAT operations will continue without change.

stJUP deposits are now stopped, and users are invited to unstake from Liquid.

Positions will continue to generate staking rewards until the next ASR distribution and the shutdown of Liquid.

stCOLLAT is not affected by this transition, and staking continues normally for them.

— Rain.fi 💧 (@RainFi_) December 11, 2025

A New President
Jupiter also appointed Xiao‑Xiao J. Zhu as its new president. After five years at KKR, where he was responsible for digital asset strategy and worked on major technology deals, Zhu will now focus on Jupiter’s expansion into “the default onchain gateway to the world.”

He said in a post on X that value in crypto “is fundamentally shifting from infrastructure to the application level,” where liquidity, distribution, and user experience form the core advantage.

After five wonderful years at KKR, I am excited to share that I am joining @JupiterExchange, the leading onchain super-app on @Solana, as President.

Here’s why.

At KKR, I had the privilege to shape digital asset strategy and to be part of the iconic TMT Private Equity and… pic.twitter.com/6cXAWwIBg5

— Xiao-Xiao J. Zhu (@xxjzhu) December 10, 2025

Under his leadership, Jupiter aims to leave a lasting impact with its role as Solana’s largest full‑stack DeFi platform.

The team oversees more than $3 billion in TVL and over $1 trillion in annualized activity across trading, lending, staking, and other product lines.

According to the new Jupiter President, the DEX will now double down on “stablecoins, payments, and an omnichain hub that connects ecosystems and liquidity layers.”

JUP Token Tanks
JUP has fallen more than 8% in the past day and nearly 39% this month. At $0.2137, the token now sits almost 90% below its all‑time high from more than two years ago.

The decline comes despite Coinbase launching spot trading for Jupiter pairs on December 9 and the launch of Ultra v3, the DEX’s upgraded trading engine.

Introducing Ultra V3 – the most advanced end to end trading engine ever created.

It delivers what traders want most:

– Best Price: Meta aggregation which includes Iris, our new router
– Best Execution: ShadowLane for optimal private txn landing & Predictive Execution for… pic.twitter.com/XEubTUmKwM

— Jupiter (🐱, 🐐) (@JupiterExchange) October 17, 2025

The engine offers deeper protection against sandwich attacks, lower execution costs, and improved slippage performance

Disclaimer: Coinspeaker is committed to providing unbiased and transparent reporting. This article aims to deliver accurate and timely information but should not be taken as financial or investment advice. Since market conditions can change rapidly, we encourage you to verify information on your own and consult with a professional before making any decisions based on this content.

Solana (SOL) News, Cryptocurrency News, News

A crypto journalist with over 5 years of experience in the industry, Parth has worked with major media outlets in the crypto and finance world, gathering experience and expertise in the space after surviving bear and bull markets over the years. Parth is also an author of 4 self-published books.

Parth Dubey on LinkedIn

Pineapple Financial, a fintech firm and the largest publicly traded INJ holder, is migrating its $10 billion mortgage lending portfolio onto blockchain through Injective.

The company has already placed data for $716 million in funded mortgages on-chain. It says more than 29,000 additional loans are expected to follow.

Sponsored

Sponsored

Pineapple Financial‘s Mortgage Portfolio Moves Onchain via InjectiveIn a detailed thread on X (formerly Twitter), the company explained that the initiative anchors each loan record to a single, immutable, and verifiable reference point. According to Pineapple, each record contains more than 500 data fields.

So, the placement of detailed loan-level metadata on-chain will provide a consistent foundation for underwriting, servicing, and investor reporting.

“This represents a major step in modernizing how mortgage data is stored, verified, and used across our entire operation,” Pineapple Financial said.

It also enhances compliance and auditability. An on-chain record provides a continuous, tamper-evident trail of every update. This streamlines regulatory reporting and eliminates much of the manual reconciliation that typically comes with managing large loan portfolios.

Pineapple Financial added that updates to mortgage files are tied to immutable on-chain fingerprints. This allows for clearer coordination across departments. It also expects efficiency gains as automated workflows replace manual checks, such as document tracking, version control, and portfolio-level analytics.

Moreover, the company said this new data foundation is designed to support additional products, including a Mortgage Data Marketplace and Pineapple Prime.

Sponsored

Sponsored

“Our goal is a faster and more transparent mortgage ecosystem built on verifiable data. By standardizing loan-level information now, we create the conditions for automation, improved risk management, and new financial products that were not feasible under legacy systems. Pineapple has already tokenized data for $716 million in funded mortgages onchain, with more than 29,000 loans set to follow,” the post read.

The firm also noted that it chose Injective for this initiative because of the network’s high-throughput and security features. According to Pineapple Financial,

“Injective supplies the infrastructure needed for this scale. Its high-security and high-throughput infrastructure allows us to verify rich loan-level data while maintaining full ownership of the platform, data structures, and customer-facing products built on top of it.”

It is also worth noting that Pineapple Financial holds Injective’s native token, INJ, as a reserve asset. The firm launched its digital asset treasury strategy in September. CoinGecko data shows it has 678,353 INJ.

Retail interest in INJ has risen alongside institutional activity. Data from Token Terminal shows Injective’s daily active users jumped to 77,600 in December, a steep increase from just 6,900 at the start of the year.

Injective Daily Users. Source: Token TerminalNonetheless, this has not translated into price strength. BeInCrypto Markets data revealed that INJ has declined 30.1% over the past month, trailing the broader crypto market.

Injective (NJ) Price Performance. Source: BeInCrypto MarketsAt the time of press, the altcoin was trading at $5.37, representing a 4.83% decline in the past 24 hours.

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with respect to the proposed acquisition of the Company by Alcon Inc. (“Alcon”) (NYSE: ALC). In addition, Broadwood released a new presentation explaining why it continues to oppose the proposed transaction, which can be viewed here. Broadwood, which owns 3.

U.S. lawmakers have urged the SEC’s Paul Atkins to implement a new executive order that could let Americans invest in Bitcoin and other digital assets inside 401(k) retirement plans. 

If approved, this move may unlock trillions in long-term retirement capital for the crypto market, which could push the bitcoin price toward $250K.

Lawmakers Ask SEC to Open the $12.5 Trillion 401(k) Market to CryptoOn December 11, U.S. lawmakers sent a formal letter to the SEC Chairman Paul Atkins, showing support for President Trump’s executive order that aims to allow alternative assets like Bitcoin in retirement plans.

The order, signed in August 2025, directs the Department of Labor and the SEC to update rules that currently limit what 401(k) plans can offer.

The goal of this letter is to give everyday workers the same investment choices that large pension funds enjoy. U.S. 401(k) plans hold around $12.5 trillion, and even a small opening for Bitcoin or other crypto assets could bring billions of dollars into the market.

Meanwhile, Lawmakers asked the SEC to speed up these changes so people can invest in more than just stocks and bonds.

Institutional Adoption May Arrive Faster Than ExpectedIndustry experts believe this policy shift could be a major turning point for crypto in traditional finance. Coinbase’s CEO recently said that Bitcoin and other cryptocurrencies will eventually become a normal part of “everyone’s 401(k).”

Some companies are already preparing for this change. For example, ForUsAll has partnered with Coinbase Institutional to let employees put up to about 5% of their 401(k) savings into crypto.

This shows that the system is already in place and could expand quickly if national rules are updated.

Small 401(k) Allocations Could Push Bitcoin Toward $250,000The shift complements other industry developments. U.S. spot Bitcoin ETFs from major firms like BlackRock and Fidelity now hold tens of billions of dollars and are widely available in IRAs and brokerage accounts. 

Investors and retirement savers alike are already using these products to gain Bitcoin exposure.

If 401(k) plans also start adding Bitcoin, even a small amount like 1–3%, it could bring tens of billions in new buying. 

Crypto analyst predict that such steady demand can push BTC price toward $250,000.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

The fund offers exposure to physical gold bars vaulted and insured in Singapore, with traditional custody and an option for in-kind redemption. Dec 11, 2025, 11:59 a.m.

Marketnode and Singapore-based asset manager Lion Global Investors are bringing the latter's Singapore Physical Gold Fund onchain on Solana, offering exposure to gold bars fully vaulted and insured in Singapore.

The fund lets investors subscribe to and redeem units onchain through Marketnode’s distribution network while keeping traditional custody, full insurance on allocated bars and an option for in-kind redemption, according to an emailed announcement on Thursday.

STORY CONTINUES BELOW

LionGlobal's Enhanced Liquidity funds in SGD and USD will also be available through the same platform.

Tokenized gold's market capitlaization has now topped the $4.1 billion mark according to CoinGecko. Earlier this week, Bhutan unveiled TER, a sovereign-backed gold token on Solana tied to state reserves, following soon after Kyrgyzstan introduced USDKG, a gold-backed stablecoin pegged to the U.S. dollar.

Rising gold prices, which hit a record $4,400 an ounce in October before correcting to $4,200, and clearer rules such as the U.S. GENIUS Act have provided a tailwind to the tokenized gold market, which is dominated Tether’s XAUT and Paxos’ PAXG.

AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Sky's Keel Starts $500M Investment Campaign to Boost RWAs on Solana

11 minutes ago

The Tokenization Regatta aims to allocate funds and support to projects bringing tokenized real-world assets to the Solana network.

What to know:

Keel has launched a $500 million campaign to attract real-world assets (RWAs) to the Solana network.The initiative, called the Tokenization Regatta, offers capital allocation and support to selected projects issuing tokenized assets on Solana.More than 40 institutions have shown interest, Keel contributor Cian Breathnach said.Read full story

American Bitcoin Corp. reported a fresh addition to its Bitcoin reserve after buying 416 BTC, bringing its total holdings to around 4,783 coins.

According to company disclosures and market reports, American Bitcoin (NASDAQ: ABTC) acquired about 416 BTC in the week ending December 8, increasing its on-balance stash to roughly 4,783 BTC. The purchase came from a combination of mined coins and selective market acquisitions, the company said.

American Bitcoin Boosts Holdings
The cash value of the latest pick-up was roughly in the $38 million range when reported, based on market prices at the time. That addition places the firm among the larger corporate BTC holders and increases the amount of Bitcoin the company holds for treasury purposes.

Reports have linked the buying to the firm’s stated strategy of growing its reserve alongside ongoing mining operations.

Shares Slide While Reserves Grow
While the balance sheet shows accumulation, the stock has struggled. Since ABTC’s market debut in September, shares have fallen by more than 70% from earlier highs, and the company has faced volatile trading as lock-up periods and market swings played out.

BTCUSD now trading at $90,310. Chart: TradingView
Some analysts continue to cover the name, but investors watching the share price have been cautious even as the firm expanded its Bitcoin holdings.

Mining, Custody And Pledges
Based on reports, the newly reported total includes coins held in custody and some that are pledged under agreements tied to miner purchases. The company noted that a portion of its BTC comes directly from mining operations while other pieces were bought on the market.

That mixed supply route means not all additions are simple open-market buys; some are internal production converted to treasury stock.

Satoshis Per Share And What Investors See
According to the company’s latest breakdown, its Satoshis Per Share (SPS) metric rose as a result of the accumulation, giving investors a clearer read on how much Bitcoin each share represents.

The metric is being used by some market watchers to compare ABTC’s treasury strength against other public firms. Analysts have pointed to the SPS figure in their notes while also flagging the stock’s recent pressure.

Family Backing And Public Profile
American Bitcoin was launched with backing from the Trump family and other partners, and the firm’s public profile has been higher than many peers because of that link.

Reports have highlighted the involvement of Eric Trump and Donald Trump Jr., while also referring to US President Donald Trump as part of the broader family context that has helped draw attention to the business.

Featured image from Unsplash, chart from TradingView

In brief
The man behind the TerraLUNA/UST ecosystem crash of 2022 will be sentenced later today in New York.
He already pleaded guilty to crimes such as conspiracy to commit commodities fraud, securities fraud, and wire fraud in August.
Prosecutors asked the court to sentence Kwon to 12 years, citing his guilty plea among other factors.
Disgraced Terraform Labs founder Do Kwon is set to be sentenced in a Manhattan court later today, December 11, by U.S. District Judge Paul Engelmayer.

Do Kwon, 33, pleaded guilty to a basket of fraud charges in August, following an international run from the law, including conspiracy to commit commodities fraud, securities fraud, and wire fraud. The South Korean entrepreneur admits to defrauding investors by making false claims about his company’s blockchain products.

He was arrested in March 2023 in the Balkan country of Montenegro while using a forged passport before being extradited to the U.S. in December 2024. His journey to evade arrest also took him through the United Arab Emirates and Singapore.

In 2022, his company’s TerraLUNA/UST ecosystem collapsed, causing losses of up to $40 billion for investors and sending severe shockwaves through the broader crypto market, impacting defunct crypto exchange FTX and crypto lender Celsius.

Terra's UST was branded as an “algorithmic stablecoin,” meaning its value wasn’t backed by traditional assets like U.S. Treasuries, unlike Circle’s USDC or Tether’s USDT.

According to AP News, official federal sentencing guidelines recommend a prison term of about 25 years. In filings earlier this month, prosecutors asked the court to sentence Kwon to 12 years, citing his guilty plea, his time served in Montenegro, and the fact that he is also expected to face charges in his native South Korea.

“I alone am responsible for everyone’s pain,” Kwon said in a letter to the judge. “The community looked to me to know the path, and I in my hubris led them astray.”

He added: “I made misrepresentations that came from a brashness that is now a source of deep regret.”

According to AP, Kwon’s lawyers have requested that his sentence be limited to five years, arguing that his conduct was driven not by greed but by “hubris and desperation.” Do Kwon is also set to forfeit $19.3 million, as well as some of his properties, as part of a plea deal.

Crypto sentencing in 2025Jail sentences for the best-known crypto criminals have varied widely. FTX founder Sam Bankman-Fried was sentenced to 25 years for his offenses in March 2024. Meanwhile, CEO of crypto investment firm Celsius, Alex Mashinsky, was given 12 years in May 2025.

Binance founder Changpeng Zhao was handed a sentence of four months in federal prison in April 2024 for failing to maintain an effective anti–money laundering program on the platform. He was pardoned by President Donald Trump in October 2025.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

13h05 ▪
4
min read ▪ by
Ifeoluwa O.

Summarize this article with:

Bitcoin has seen steady gains since the start of the week, closing in positive territory over the last four days. But these short-term gains don’t tell the full story. Under the surface, market conditions have shifted in recent weeks. Fewer coins are moving onto exchanges, suggesting that investors are not rushing to sell, a key sign that selling pressure is easing.

In brief

Bitcoin moving to exchanges has dropped dramatically in recent weeks, signaling weaker selling activity.
This reduction in offloading from whales eases market pressure and creates conditions for steadier price movement in the near term.
Continued low selling could allow Bitcoin to approach resistance levels near $102,000 and test higher thresholds.

Bitcoin Sees Easing Selling Pressure
Bitcoin briefly fell to $80,000 on November 21 but has since climbed to a one-month high near $94,000. This recovery comes as fewer coins are being moved onto exchanges and selling from large holders has slowed, trends that generally help support market stability. 

Over the past three weeks, exchange deposits have dropped sharply from 88,000 BTC to 21,000 BTC, reflecting a gradual reduction in selling activity that had been building. Much of this slowdown is due to the actions of large investors and whales. Specifically, their share of exchange deposits fell from 47% in mid-November to 21%, while the average size of their transactions shrank 36%, declining from 1.1 BTC to 0.7 BTC. 

These shifts in market behavior were already in place ahead of today’s Federal Reserve decision, which cut the key interest rate by 25 basis points to 3.5%–3.75%, marking the third reduction in 2025.

Bitcoin Set for Near-Term Gains
The slowdown in selling comes after a period of heavy market losses, with Bitcoin dipping below $100,000 on November 13 and whales and short-term traders recording $646 million in realized losses, marking the largest losses observed since mid-year.

In total, net losses have reached roughly $3.2 billion in recent weeks, a level that appears to have cleared out more vulnerable holders and lessened the pressure of forced selling. While such losses can drive steep declines during weak market phases, once the bulk of this pressure eases, it often creates conditions for steadier price movement.

If selling continues to remain low, Bitcoin could see further upside in the near term, with potential levels to watch reflecting both on-chain metrics and historical resistance points.

Bitcoin may rise toward $99,000, which aligns with the lower range of the Trader On-chain Realized Price indicator, suggesting initial upside potential if current market conditions hold
Looking higher, key resistance is observed at $102,000, near the one-year moving average, and around $112,000, corresponding with the upper range of the same on-chain metric, indicating areas where upward momentum could face stronger selling pressure

Rate Cut Offers Relief, but History Weighs on Momentum
Alongside these resistance levels, the recent Federal Reserve rate cut could influence short-term price action, potentially prompting a brief relief rally. However, historical trends suggest Bitcoin often faces downward pressure following FOMC announcements, with analyst Ali Martinez noting that in 2025, the only short-lived rally occurred in early May. 

Currently, the cryptocurrency remains in a corrective channel, trading around $93,731 with resistance between $94,000 and $96,000. Any sustained upward movement will depend on buyers overcoming these barriers to maintain momentum.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.

Join the program

A

A

Lien copié

Ifeoluwa O.

Ifeoluwa specializes in Web3 writing and marketing, with over 5 years of experience creating insightful and strategic content. Beyond this, he trades crypto and is skilled at conducting technical, fundamental, and on-chain analyses.

DISCLAIMER

The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.

December 11, 2025 7:00 AM EST | Source: Safe Supply Streaming Co Ltd.
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, is pleased to announce that, further to its news releases dated November 24, 2025 and December 9, 2025, it has closed its upsized non-brokered private placement (the "Offering") for total gross proceeds of $935,000. The Offering was upsized from an initial $500,000 target to accommodate high investor demand. Gross proceeds were raised through the issuance of 18,700,000 units (the "Units") at a price of $0.05 per Unit.

Each Unit consists of one common share of the Company (each, a "Common Share") and one-half of one warrant. Each whole warrant (each, a "Warrant") entitles the holder to purchase one additional Common Share at an exercise price of $0.075 per share for a period of 24 months from the date of issuance. In connection with the Offering, the Company paid finder's fees on certain subscriptions in accordance with applicable securities laws and CSE policies, consisting of cash commissions of $65,450 and 1,309,000 broker warrants in respect of investors introduced by eligible finders. Each broker warrant is exercisable to acquire one additional Unit at $0.05 for a period of 24 months from the date of issuance. PowerOne Capital Markets Limited acted as finder in connection with a portion of the Offering.

The net proceeds from the Offering are intended to be used to fund the licensing fee and related obligations under the Company's licensing agreement with Healthy Sprays, as well as for general corporate and working capital purposes. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable Canadian securities laws.

"The strong demand for this financing from existing shareholders, members of our management team, and new strategic investors underscores the confidence in our strategy and the momentum we are building across our portfolio of products," said Geoff Benic, Chief Executive Officer of Safe Supply. "With the successful close of this upsized financing, we are well-capitalized to advance the commercialization of the Healthy Sprays GLP-1 technology, continue to grow sales of our current product lines, and execute on our vision of delivering accessible, science-driven wellness solutions at scale."

MI 61-101 Disclosure

An insider of the Company participated in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101, as the fair market value of the securities issued to the insider under the Offering does not exceed $2,500,000.

The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

About Safe Supply Streaming Co Ltd.

Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) is a publicly-traded company focused on advancing innovation in healthcare, wellness, and emerging technologies. Through strategic acquisitions, partnerships, and capital investments, Safe Supply is building a diversified portfolio of companies that leverage data, science, and digital platforms to improve outcomes, drive accessibility, and scale impact. Operating at the intersection of public health and technology, Safe Supply supports evidence-informed solutions to urgent societal needs. Its wholly-owned subsidiaries, including Safety Strips Tech Corp. and Drug Lab 118 Ltd., develop proprietary rapid testing technologies such as fentanyl and drink-spiking detection products which are designed to enhance health outcomes and enhance public safety and wellness.

For more information, please visit www.safesupply.com.

On behalf of the Board of Directors of Safe Supply Streaming Co Ltd.

"Geoff Benic"
Geoff Benic, Chief Executive Officer

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this news release and has neither approved nor disapproved its contents.

Cautionary Note and Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are based on current expectations, estimates, projections, and assumptions made by the Company in light of its experience and perception of historical trends, current conditions, and anticipated future developments, as well as other factors the Company believes are appropriate in the circumstances.

Forward-looking statements in this release include, but are not limited to the use of proceeds of the proposed private placement Offering.

Forward-looking statements are inherently subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risk general economic, market, and industry conditions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release.

Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. All forward-looking statements contained in this release are expressly qualified by this cautionary statement.

Not for distribution to United States Newswire Services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277725